RS62805B1 - Jedinjenja inhibitori btk - Google Patents

Jedinjenja inhibitori btk

Info

Publication number
RS62805B1
RS62805B1 RS20220028A RSP20220028A RS62805B1 RS 62805 B1 RS62805 B1 RS 62805B1 RS 20220028 A RS20220028 A RS 20220028A RS P20220028 A RSP20220028 A RS P20220028A RS 62805 B1 RS62805 B1 RS 62805B1
Authority
RS
Serbia
Prior art keywords
btk inhibitor
inhibitor compounds
compounds
btk
inhibitor
Prior art date
Application number
RS20220028A
Other languages
English (en)
Inventor
Kenneth James Henry Jr
Albert Khilevich
Steven Lee Kuklish
Katherine Marie Partridge
Steven James Quimby
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of RS62805B1 publication Critical patent/RS62805B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RS20220028A 2017-11-06 2018-10-30 Jedinjenja inhibitori btk RS62805B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762581967P 2017-11-06 2017-11-06
EP18801226.4A EP3707133B1 (en) 2017-11-06 2018-10-30 Btk inhibitor compounds
PCT/US2018/058104 WO2019089512A1 (en) 2017-11-06 2018-10-30 Btk inhibitor compounds

Publications (1)

Publication Number Publication Date
RS62805B1 true RS62805B1 (sr) 2022-02-28

Family

ID=64277913

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20220028A RS62805B1 (sr) 2017-11-06 2018-10-30 Jedinjenja inhibitori btk

Country Status (34)

Country Link
US (1) US11542249B2 (sr)
EP (1) EP3707133B1 (sr)
JP (1) JP6920553B2 (sr)
KR (1) KR102410202B1 (sr)
CN (1) CN111278818B (sr)
AR (1) AR113796A1 (sr)
AU (1) AU2018360478B2 (sr)
BR (1) BR112020006749A2 (sr)
CA (1) CA3080123C (sr)
CL (1) CL2020001089A1 (sr)
CR (1) CR20200183A (sr)
CY (1) CY1124994T1 (sr)
DK (1) DK3707133T3 (sr)
DO (1) DOP2020000103A (sr)
EA (1) EA039398B1 (sr)
EC (1) ECSP20024395A (sr)
ES (1) ES2904843T3 (sr)
HR (1) HRP20220178T1 (sr)
HU (1) HUE057987T2 (sr)
IL (1) IL273778B (sr)
JO (1) JOP20200104A1 (sr)
LT (1) LT3707133T (sr)
MA (1) MA50561B1 (sr)
MD (1) MD3707133T2 (sr)
MX (1) MX2020004435A (sr)
PE (1) PE20201168A1 (sr)
PL (1) PL3707133T3 (sr)
PT (1) PT3707133T (sr)
RS (1) RS62805B1 (sr)
SG (1) SG11202003178PA (sr)
SI (1) SI3707133T1 (sr)
TW (1) TWI694995B (sr)
UA (1) UA126079C2 (sr)
WO (1) WO2019089512A1 (sr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022533968A (ja) * 2019-05-23 2022-07-27 ノバルティス アーゲー ブルトン型チロシンキナーゼ阻害剤を使用したシェーグレン症候群を処置する方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2205564B1 (en) * 2007-10-23 2014-07-30 F. Hoffmann-La Roche AG Novel kinase inhibitors
CN103038233B (zh) * 2010-05-07 2017-06-20 吉利德康涅狄格有限公司 吡啶酮和氮杂吡啶酮化合物及使用方法
AR082590A1 (es) * 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
KR20140007954A (ko) 2011-06-10 2014-01-20 메르크 파텐트 게엠베하 Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법
WO2014093230A2 (en) 2012-12-10 2014-06-19 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
GB2516303A (en) * 2013-07-18 2015-01-21 Redx Pharma Ltd Compounds
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors

Also Published As

Publication number Publication date
US20200290997A1 (en) 2020-09-17
KR102410202B1 (ko) 2022-06-22
JOP20200104A1 (ar) 2022-10-30
TW201930293A (zh) 2019-08-01
CN111278818B (zh) 2023-03-28
CN111278818A (zh) 2020-06-12
SG11202003178PA (en) 2020-05-28
PT3707133T (pt) 2022-01-27
PE20201168A1 (es) 2020-10-28
HUE057987T2 (hu) 2022-06-28
KR20200060480A (ko) 2020-05-29
CL2020001089A1 (es) 2020-10-23
AU2018360478B2 (en) 2020-09-17
IL273778B (en) 2022-06-01
UA126079C2 (uk) 2022-08-10
MX2020004435A (es) 2020-08-06
JP6920553B2 (ja) 2021-08-18
EA202090843A1 (ru) 2020-07-24
LT3707133T (lt) 2022-01-25
HRP20220178T1 (hr) 2022-04-29
ES2904843T3 (es) 2022-04-06
WO2019089512A1 (en) 2019-05-09
DK3707133T3 (da) 2022-01-03
US11542249B2 (en) 2023-01-03
DOP2020000103A (es) 2020-09-15
JP2021501749A (ja) 2021-01-21
NZ764452A (en) 2023-09-29
CR20200183A (es) 2020-05-30
PL3707133T3 (pl) 2022-04-04
AU2018360478A1 (en) 2020-04-23
BR112020006749A2 (pt) 2020-10-06
CY1124994T1 (el) 2023-01-05
EA039398B1 (ru) 2022-01-24
MD3707133T2 (ro) 2022-07-31
MA50561B1 (fr) 2022-03-31
IL273778A (en) 2020-05-31
MA50561A (fr) 2020-09-16
EP3707133A1 (en) 2020-09-16
CA3080123A1 (en) 2019-05-09
AR113796A1 (es) 2020-06-10
ECSP20024395A (es) 2020-06-30
EP3707133B1 (en) 2021-12-15
CA3080123C (en) 2021-11-09
TWI694995B (zh) 2020-06-01
SI3707133T1 (sl) 2022-02-28

Similar Documents

Publication Publication Date Title
IL268282A (en) HIV inhibitory compounds
IL269196A (en) New inhibitors
EP3246317A4 (en) Btk inhibitor
GB201700814D0 (en) Compounds
GB201705971D0 (en) Inhibitor compounds
GB201403536D0 (en) Inhibitor compounds
HK1247607A1 (zh) P62-zz化學抑制劑
GB201513481D0 (en) Inhibitor compounds
GB201505658D0 (en) Inhibitor compounds
SG11202005870RA (en) Novel mtor inhibitor compounds
IL273778B (en) Compounds of btk inhibitors
GB201702221D0 (en) Compounds
GB201703282D0 (en) Compounds
GB201720145D0 (en) Inhibitor compounds
GB201708510D0 (en) Inhibitor compounds
GB201708502D0 (en) Inhibitor compounds
GB201708507D0 (en) Inhibitor compounds
GB201705968D0 (en) Inhibitor compounds
GB201621619D0 (en) Inhibitor compounds
GB201721662D0 (en) Compounds
GB201721665D0 (en) Compounds
GB201717530D0 (en) New compounds
GB201714049D0 (en) New compounds
GB201712289D0 (en) New compounds
GB201707966D0 (en) Compounds